We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Nanoparticles Empower Potential Universal Flu Vaccine

By LabMedica International staff writers
Posted on 05 Feb 2018
Print article
Image: A colorized negative stained transmission electron micrograph (TEM) depicting flu virus ultrastructural morphology (Photo courtesy of the CDC).
Image: A colorized negative stained transmission electron micrograph (TEM) depicting flu virus ultrastructural morphology (Photo courtesy of the CDC).
A potential "universal" flu vaccine based on double-layered protein nanoparticles loaded with the invariable portion of viral hemagglutinin produced long-lasting immunity and fully protected mice against challenge with various strains of influenza A viruses.
 
Investigators at Georgia State University (Atlanta, USA) fabricated layered nanoparticles by inserting tetrameric M2e into protein nanoparticle cores and coating these cores with crosslinked headless hemagglutinin stalk proteins. M2e (ectodomain of influenza matrix protein 2) is highly conserved in both human and avian influenza A viruses. The low immunogenicity against natural M2e can be overcome by fusing M2e to an appropriate carrier particle. Protein carriers with representative headless hemagglutinin of two different phylogenetic groups were constructed and purified.
 
The investigators reported in the January 24, 2018, online edition of the journal Nature Communications that vaccinations with the resulting protein nanoparticles in mice induced robust long-lasting immunity, fully protecting the mice against challenges by influenza A viruses of the same group or both groups.
 
"What we wanted to do is to induce responses to this stalk part of the influenza surface glycoprotein, not the head part," said senior author Dr. Bao-Zhong Wang, associate professor of biomedical sciences at Georgia State University. "This way you are protected against different viruses because all influenza viruses share this stalk domain. However, this stalk domain itself is not stable, so we used a very special way to make this vaccine construct with the stalk domain and had success. We assembled this stalk domain into a protein nanoparticle as a vaccine. Once inside, the nanoparticle can protect this antigenic protein so it will not be degraded. Our immune cells have a good ability to take in this nanoparticle, so this nanoparticle is much, much better than a soluble protein to induce immune responses. We are developing a universal influenza vaccine that would not need to change the vaccine type every year because it is universal and can protect against any influenza virus."
 
In addition to their role in a universal flu vaccine, the physiologically activated disassembly of the protein nanoparticles after uptake into cells implies a wide potential for protein drug delivery and controlled release.
 
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.